[go: up one dir, main page]

WO2009098612A3 - Polymorphic form of a [1, 2, 4] triazolo [4, 3-a] pyridine derivative for treating inflammatory diseases - Google Patents

Polymorphic form of a [1, 2, 4] triazolo [4, 3-a] pyridine derivative for treating inflammatory diseases Download PDF

Info

Publication number
WO2009098612A3
WO2009098612A3 PCT/IB2009/050351 IB2009050351W WO2009098612A3 WO 2009098612 A3 WO2009098612 A3 WO 2009098612A3 IB 2009050351 W IB2009050351 W IB 2009050351W WO 2009098612 A3 WO2009098612 A3 WO 2009098612A3
Authority
WO
WIPO (PCT)
Prior art keywords
triazolo
polymorphic form
inflammatory diseases
treating inflammatory
pyridine derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2009/050351
Other languages
French (fr)
Other versions
WO2009098612A2 (en
Inventor
Kenneth John Butcher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd Great Britain
Original Assignee
Pfizer Ltd Great Britain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK09708402.4T priority Critical patent/DK2303267T3/en
Priority to EP09708402.4A priority patent/EP2303267B1/en
Priority to HK11101504.4A priority patent/HK1147481B/en
Priority to CN2009801041294A priority patent/CN101939320B/en
Priority to MX2010008535A priority patent/MX2010008535A/en
Priority to ES09708402T priority patent/ES2423991T3/en
Priority to CA2712574A priority patent/CA2712574C/en
Priority to BRPI0907463A priority patent/BRPI0907463A2/en
Priority to NZ587094A priority patent/NZ587094A/en
Priority to AU2009211072A priority patent/AU2009211072B2/en
Priority to US12/865,889 priority patent/US8222273B2/en
Application filed by Pfizer Ltd Great Britain filed Critical Pfizer Ltd Great Britain
Priority to PL09708402T priority patent/PL2303267T3/en
Priority to SI200930680T priority patent/SI2303267T1/en
Priority to KR1020137015900A priority patent/KR20130087048A/en
Priority to KR1020107016846A priority patent/KR101422318B1/en
Publication of WO2009098612A2 publication Critical patent/WO2009098612A2/en
Publication of WO2009098612A3 publication Critical patent/WO2009098612A3/en
Priority to IL206948A priority patent/IL206948A/en
Priority to ZA2010/05137A priority patent/ZA201005137B/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)

Abstract

The present invention relates to a polymorphic form B of Λ/-[3-tert-butyl-1-(3- chloro-4-hydroxyphenyl)-1 H-pyrazol-5-yl]-N-{2-[(3-{2-[(2-hydroxyethyl)sulfanyl] phenyl}[1,2.4]triazolo[4,3-a]pyridin-6-yl)sulfanyl]benzyl}urea (I) as defined herein. This polymorph is useful in the treatment of various conditions, particularly in the treatment of inflammatory conditions such as chronic obstructive pulmonary disease.
PCT/IB2009/050351 2008-02-04 2009-01-28 Polymorphic form of a [1, 2, 4] triazolo [4, 3-a] pyridine derivative for treating inflammatory diseases Ceased WO2009098612A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
US12/865,889 US8222273B2 (en) 2008-02-04 2009-01-28 Polymorphic form of a [1,2,4]triazole[4,3-A] pyridine derivative inflammatory diseases
HK11101504.4A HK1147481B (en) 2008-02-04 2009-01-28 Polymorphic form
CN2009801041294A CN101939320B (en) 2008-02-04 2009-01-28 Polymorphic form
MX2010008535A MX2010008535A (en) 2008-02-04 2009-01-28 Polymorphic form of a [1, 2, 4] triazolo [4, 3-a] pyridine derivative for treating inflammatory diseases.
ES09708402T ES2423991T3 (en) 2008-02-04 2009-01-28 Polymorphic form of a derivative of [1,2,4] triazolo [4,3-a] pyridine for the treatment of inflammatory diseases
CA2712574A CA2712574C (en) 2008-02-04 2009-01-28 Polymorphic form of a [1,2,4]triazolo[4,3-a]pyridine derivative for treating inflammatory diseases
BRPI0907463A BRPI0907463A2 (en) 2008-02-04 2009-01-28 polymorphic form of a [1,2,4] triazole [4,3-a] pyridine derivative for treating inflammatory diseases
NZ587094A NZ587094A (en) 2008-02-04 2009-01-28 Polymorphic form of a [1, 2, 4] triazolo [4, 3-a] pyridine derivative for treating inflammatory diseases
PL09708402T PL2303267T3 (en) 2008-02-04 2009-01-28 Polymorphic form of a [1, 2, 4] triazolo [4, 3-a]pyridine derivative for treating inflammatory diseases
DK09708402.4T DK2303267T3 (en) 2008-02-04 2009-01-28 POLYMORPH FORM OF A [1,2,4] -TRIAZOLO- [4,3-A] PYRIDINE DERIVATIVE FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP09708402.4A EP2303267B1 (en) 2008-02-04 2009-01-28 Polymorphic form of a [1, 2, 4] triazolo [4, 3-a]pyridine derivative for treating inflammatory diseases
AU2009211072A AU2009211072B2 (en) 2008-02-04 2009-01-28 Polymorphic form of a [1, 2, 4] triazolo [4, 3-A] pyridine derivative for treating inflammatory diseases
SI200930680T SI2303267T1 (en) 2008-02-04 2009-01-28 Polymorphic form of a s1, 2, 4c triazolo s4, 3-acpyridine derivative for treating inflammatory diseases
KR1020137015900A KR20130087048A (en) 2008-02-04 2009-01-28 Polymorphic form of a [1,2,4]triazolo[4,3-a]pyridine derivative for treating inflammatory diseases
KR1020107016846A KR101422318B1 (en) 2008-02-04 2009-01-28 Polymorphic form of a [1,2,4]triazolo[4,3-a]pyridine derivative for treating inflammatory diseases
IL206948A IL206948A (en) 2008-02-04 2010-07-12 Polymorphic form of n-[3-tert-butyl-1-(3-chloro-4-hydroxyphenyl)-1h-pyrazol-5-yl]-n'-{2-[(3-{2-[(2-hydroxyethyl)sulfanyl] phenyl}[1,2,4]triazolo[4,3-a]pyridin-6-yl)sulfanyl]benzyl}urea, processes for its preparation, pharmaceutical compositions comprising it and use thereof for the preparation of compositions for treating various inflammatory diseases
ZA2010/05137A ZA201005137B (en) 2008-02-04 2010-07-19 Polymorphic form of a [1,2,4]thiazolo[4,3-a]pyridine derivative for treating inflammatory diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2587908P 2008-02-04 2008-02-04
US61/025,879 2008-02-04

Publications (2)

Publication Number Publication Date
WO2009098612A2 WO2009098612A2 (en) 2009-08-13
WO2009098612A3 true WO2009098612A3 (en) 2009-10-08

Family

ID=40911989

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/050351 Ceased WO2009098612A2 (en) 2008-02-04 2009-01-28 Polymorphic form of a [1, 2, 4] triazolo [4, 3-a] pyridine derivative for treating inflammatory diseases

Country Status (22)

Country Link
US (1) US8222273B2 (en)
EP (1) EP2303267B1 (en)
JP (1) JP5344942B2 (en)
KR (2) KR101422318B1 (en)
CN (1) CN101939320B (en)
AR (1) AR070411A1 (en)
AU (1) AU2009211072B2 (en)
BR (1) BRPI0907463A2 (en)
CA (1) CA2712574C (en)
CY (1) CY1114389T1 (en)
DK (1) DK2303267T3 (en)
ES (1) ES2423991T3 (en)
IL (1) IL206948A (en)
MX (1) MX2010008535A (en)
NZ (1) NZ587094A (en)
PL (1) PL2303267T3 (en)
PT (1) PT2303267E (en)
RU (1) RU2448966C1 (en)
SI (1) SI2303267T1 (en)
TW (1) TWI391391B (en)
WO (1) WO2009098612A2 (en)
ZA (1) ZA201005137B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
US9061352B2 (en) 2010-08-30 2015-06-23 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
EP2464346A1 (en) 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
EP3470057B1 (en) 2010-09-29 2021-11-03 Pulmatrix Operating Company, Inc. Cationic dry powders comprising magnesium salt
WO2013052844A1 (en) 2011-10-07 2013-04-11 Pulmatrix, Inc. Methods for treating and diagnosing respiratory tract infections
EP2788345B1 (en) 2011-12-09 2020-06-10 Chiesi Farmaceutici S.p.A. Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphtalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract
CN105693716A (en) * 2016-03-01 2016-06-22 孙霖 Crystal form A and preparing method
CN105646484A (en) * 2016-03-01 2016-06-08 孙霖 Crystal form B and preparation method
GB201611712D0 (en) 2016-07-02 2016-08-17 Hvivo Services Ltd Methods and compounds for the treatment or prevention of severe or persistent influenza
GB201721793D0 (en) 2017-12-22 2018-02-07 Hvivo Services Ltd Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006018718A2 (en) * 2004-08-12 2006-02-23 Pfizer Limited Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP990182A2 (en) 1998-06-11 2000-02-29 Du Pont Pharm Co Crystalline efavirenz
US6541493B1 (en) * 1998-11-20 2003-04-01 Mitsubishi Chemical Corporation Crystals of 5-[{6-(2-fluorobenzyl)oxy-2-naphthyl}methyl]-2,4-thiazolidinedione
US7847112B2 (en) 2004-07-16 2010-12-07 Health Science Funding, LLC Polymorphs of atovaquone and process of preparation thereof
GB0418015D0 (en) * 2004-08-12 2004-09-15 Pfizer Ltd New compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006018718A2 (en) * 2004-08-12 2006-02-23 Pfizer Limited Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAIRA M R: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, 1 January 1998 (1998-01-01), pages 163 - 208, XP001156954 *

Also Published As

Publication number Publication date
JP5344942B2 (en) 2013-11-20
TW200944524A (en) 2009-11-01
ZA201005137B (en) 2011-03-30
RU2010132639A (en) 2012-02-10
EP2303267B1 (en) 2013-07-03
BRPI0907463A2 (en) 2019-09-24
PT2303267E (en) 2013-08-05
CA2712574A1 (en) 2009-08-13
KR20130087048A (en) 2013-08-05
TWI391391B (en) 2013-04-01
SI2303267T1 (en) 2013-09-30
CN101939320A (en) 2011-01-05
CN101939320B (en) 2013-11-20
DK2303267T3 (en) 2013-09-02
EP2303267A2 (en) 2011-04-06
PL2303267T3 (en) 2013-11-29
US8222273B2 (en) 2012-07-17
JP2009185028A (en) 2009-08-20
AU2009211072A1 (en) 2009-08-13
KR101422318B1 (en) 2014-07-22
CA2712574C (en) 2014-01-07
AU2009211072B2 (en) 2014-01-23
NZ587094A (en) 2011-07-29
CY1114389T1 (en) 2016-08-31
RU2448966C1 (en) 2012-04-27
AR070411A1 (en) 2010-04-07
KR20100108409A (en) 2010-10-06
MX2010008535A (en) 2010-08-30
IL206948A0 (en) 2010-12-30
US20110003848A1 (en) 2011-01-06
IL206948A (en) 2014-12-31
HK1147481A1 (en) 2011-08-12
WO2009098612A2 (en) 2009-08-13
ES2423991T3 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
WO2009098612A3 (en) Polymorphic form of a [1, 2, 4] triazolo [4, 3-a] pyridine derivative for treating inflammatory diseases
WO2010030785A3 (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
WO2007087441A3 (en) Substituted aromatic compounds for inflammation and immune-related uses
NO20083567L (en) Hydantoin derivatives for the treatment of inflammatory disorders
WO2008045664A3 (en) Heterocyclic pde4 inhibitors as antiinflammatory agents
WO2007087442A3 (en) Substituted biaryl compounds for inflammation and immune-related uses
WO2007087204A3 (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
WO2007087429A3 (en) Phenyl and pyridyl compounds for inflammation and immune-related uses
EA200900821A1 (en) DERIVATIVES 1-AMINOMETHIL-L-PHENYLCICLOGEXANE AS DPP-IV INHIBITORS (DIPEPTIDYLPEPTIDASE-IV)
WO2007084391A3 (en) Thiazole compounds as protein kinase b ( pkb) inhibitors
WO2010008847A3 (en) Pi3k/m tor inhibitors
WO2011112766A3 (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2008060391A3 (en) 2- [l-phenyl-5-hydr0xy-4alpha-methyl-hexahydr0cycl0penta[f] indaz0l-5-yl] ethyl phenyl derivatives as glucocorticoid receptor ligands
WO2013049726A3 (en) Processes for making compounds useful as inhibitors of atr kinase
WO2010028192A8 (en) Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
WO2006122806A3 (en) 1,3-dihydro-imidazo [4,5-c] quinolin-2-ones as lipid kinase inhibitors
WO2008027584A3 (en) 5- (2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase
WO2007150026A3 (en) Purinone derivatives as hm74a agonists
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2012044727A3 (en) Manufacturing process for pyrimidine derivatives
WO2011112731A3 (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
WO2006127893A3 (en) Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
WO2009013348A3 (en) Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
WO2007056167A3 (en) Substituted-(quinazolinyl)phenyl thiophenyl-sulfonylureas, methods for making and intermediates thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980104129.4

Country of ref document: CN

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2009211072

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 206948

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2712574

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 5216/DELNP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20107016846

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2009211072

Country of ref document: AU

Date of ref document: 20090128

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 587094

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 12865889

Country of ref document: US

Ref document number: 2010132639

Country of ref document: RU

Ref document number: MX/A/2010/008535

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009708402

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0907463

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100722